Dr Mike Mitchell of Panmure Gordon said this morning about Allergy Therapeutics: “This morning, Allergy Therapeutics has announced a strong trading update for the first four months of 2016 (+12% like-for-like constant currency growth, or +15% including the Alerpharma acquisition which was completed June 2015) which, considering the flat market backdrop and the reported FY15 constant currency sales growth of 11%, represents a robust performance. In this context, the company has announced the proposed placing via accelerated bookbuild to raise up to £12m which will be targeted to support the development of two specific product opportunities, including the first entry into food allergy with Polyvac Peanut, and the supported development of Acarovac Quattro (house dust mite). These represent substantial new market opportunities and we will be updating our view (forecasts, valuation) in light of the further announcements”
Campaign launched to prevent food allergy-related deaths and illness on Teesside
A new campaign has been launched with the aim of preventing food allergy-related illness and deaths across Teesside. Targeted at restaurants and food outlets, all 12 local authorities in the North East have joined forces to